Oral Ketamine Formulation Shows Promise for Treatment-Resistant Depression

Clinical trial results published in JAMA Network Open indicate that Ketabon (KET01), an oral prolonged-release ketamine formulation, demonstrates early antidepressant effects in patients with treatment-resistant depression. The study also highlighted favorable tolerability, with minimal dissociative or cardiovascular side effects. These findings suggest potential for at-home administration, addressing current limitations of ketamine-based therapies.